Table 1.

Primary HPV test by cervical cytology and age group.

	Total	(%)	34–43 years	44–69 years
HPV positivea
Totala	3111	100	1507	1604
No cytology or unsatisfactory	229	7.4	120	109
NILM	1278	41.1	545	733
Had repeat HPV testb	626	49.0b	262	364
ASC-US	717	23.0	329	388
LSIL	333	10.7	190	143
High-gradec	554	17.8	323	231
HPV 16
Total	650	100	365	285
No cytology or unsatisfactory	49	7.5	25	24
NILM	201	30.9	99	102
Had repeat HPV testb	116	57.7b	63	53
ASC-US	132	20.3	67	65
LSIL	79	12.2	55	24
High-gradec	189	29.1	119	70
HPV 18
Total	221	100	119	102
No cytology or unsatisfactory	20	9.0	13	7
NILM	74	33.5	33	41
Had repeat HPV testb	43	58.1b	19	24
ASC-US	53	24.0	29	24
LSIL	22	10.0	11	11
High-gradec	52	23.5	33	19
HPV other high riskd
Total	2148	100	975	1173
No cytology or unsatisfactory	150	7.0	77	73
NILM	981	45.7	403	578
Had repeat HPV testb	456	46.5b	174	282
ASC-US	498	23.2	214	284
LSIL	225	10.5	120	105
High-gradec	294	13.7	161	133

CIN cervical intraepithelial neoplasia, NILM negative for intraepithelial lesion or malignancy, ASC-US atypical squamous cells of undetermined significance, LSIL low grade squamous intraepithelial lesions.

^aTotal includes 92 (3.0%) women who were not genotyped.

^bPercentage is calculated as percent of those with NILM test who were positive upon repeat HPV test.

^cIncludes AGC, ASC-H, HSIL, and cancer.

^dIncludes HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.